Supplementary Information
EFFECTS OF CANNABIDIOL ON SYMPTOMS IN PEOPLE AT CLINICAL HIGH RISK FOR PSYCHOSIS
Embedded Files
World Psychiatry 2024
Sagnik Bhattacharyya, Elizabeth Appiah-Kusi, Robin Wilson, Aisling O’Neill, Michael Brammer, Steven Williams, Jesus Perez, Matthijs G Bossong,
Philip McGuire
Supplementary Figure 1
Supplementary Table 3. Adverse events* reported at 21 days
*Assessed using the UKU side-effect rating scale1.
Out of 15 patients in the CHR-PLB (6 females) and 15 in the CHR-CBD (6 females) group with tolerability data, no one reported galactorrhoea, gynaecomastia, increased sexual desire, ejaculatory or orgastic dysfunction, dry vagina; only 1 out 6 females in the CHR-CBD group reported menorrhagia and 1 out of 6 females in the CHR-PLB group reported amenorrhoea and 1 out of 9 males in the CHR-CBD group reported erectile dysfunction.
** Chi-square test
REFERENCES:
1. Lingjaerde O, Ahlfors UG, Bech P, Dencker SJ, Elgen K. The UKU side effect rating scale. A new comprehensive rating scale for psychotropic drugs and a cross-sectional study of side effects in neuroleptic-treated patients. Acta Psychiatr Scand Suppl 1987; 334: 1-100.
Page updated
Google Sites
Report abuse